Industry

Study: Semaglutide does not appear to raise eye complication risk

Healio Optometry3h ago1 min read

SAN DIEGO — Semaglutide use was not tied to a higher risk for non-arteritic anterior ischemic optic neuropathy, or NAION, in patients with overweight or obesity, data presented here show.The study further showed that semaglutide (Ozempic/Wegovy, Novo Nordisk) lowered the risk for NAION by 64% in patients with type 2 diabetes.As Healio previously reported, prior research suggested that semaglutide use may raise the risk for NAION and other eye complications like diabetic retinopathy, although these occurrences are rare.But Richele Corrado, DO, MPH, FACP, DABOM, a clinical associate professor

Read full article on Healio Optometry

AI Summary

Quick Take

New data presented in San Diego indicates that semaglutide use is not associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. Furthermore, the study found that semaglutide (Ozempic/Wegovy) actually reduced the risk of NAION by 64% in patients with type 2 diabetes.

Why It Matters

This study provides a critical counter-narrative to recent concerns that GLP-1 receptor agonists might trigger rare but serious ocular complications like NAION. For eye care providers, these findings offer much-needed reassurance when counseling the rapidly growing population of patients prescribed these medications for weight loss and glycemic control. The suggestion of a protective effect in diabetic patients is particularly significant, as it shifts the conversation from potential harm to a possible secondary ophthalmic benefit of systemic GLP-1 therapy.

Key Findings

Semaglutide use was not tied to a higher risk for NAION in patients with overweight or obesity.
Patients with type 2 diabetes using semaglutide experienced a 64% reduction in the risk of developing NAION.
The findings contrast with prior retrospective research that suggested a potential correlation between semaglutide and increased rates of NAION or diabetic retinopathy.

Study Snapshot

Design

Data analysis/Comparative study

Population

Patients with overweight, obesity, or type 2 diabetes

Practice Implications

Clinicians should feel more confident in the ocular safety profile of semaglutide regarding NAION, especially for patients with type 2 diabetes. While standard monitoring for diabetic retinopathy remains essential during periods of rapid glycemic improvement, these results suggest that semaglutide does not necessitate specialized NAION screening protocols beyond standard clinical care.

Who's Affected

OphthalmologistsOptometristsNeuro-ophthalmologistsRetina SpecialistsEndocrinologists

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.